Press Releases/What’s New

COP

Holiday Lights Contest Winners Announced

December 22, 2021

Once again the Neighborhood Holiday Lights Contest received enthusiastic support, with 48 Portsmouth residents participating. Mayor Rick Becksted joined members of the Citywide Neighborhood Committee and the children who did the judging to announce the winners at the City Council meeting on Monday, December 20.  Winners will receive their gift cards in a letter from the Mayor.

COP

Parking Holiday Dec 18-25, 2021

December 17, 2021

Parking payment for on-street and lot spaces managed by the City of Portsmouth is not enforced on these dates.  This parking holiday does not apply to parking in the Hanover and Foundry garages. 

PW

NHDES Installs Temporary Air Quality Monitoring Devices Near Railyard

December 17, 2021

The City of Portsmouth has authorized the NH Department of Environmental Services (NHDES) to place temporary air quality monitoring devices in locations surrounding the Foundry Place Garage. The air quality study was authorized by NHDES in response to City concerns regarding air quality complaints from the neighborhood and residents’ reports of emissions from locomotives in the railyard.

COP

Foundation for Seacoast Health Announces Potential Plan to Sell Community Campus to City

December 16, 2021

The Foundation for Seacoast Health has announced their intent to sell the Community Campus building and surrounding 34 acres to the City of Portsmouth. Following a three-year strategic planning process and a goal to maintain its original vision as a multi-tenant non-profit center, while adding new resources to benefit the community, the Foundation has determined the City to be the ideal buyer to manage the Campus.

COP

Evusheld Treatment

December 16, 2021

What is the “Evusheld” treatment and how does it work?

Evusheld is a pre-COVID protection option developed by AstraZeneca that combines two monoclonal antibodies (tixagevimab and cilgavimab) in one injection. In a study of persons who were at high risk of severe illness, hospitalization, or death from COVID-19 because they were immunocompromised or ineligible to receive a COVID-19 vaccination, Evusheld was shown to reduce the risk of developing COVID-19 compared to those who received a placebo.